Trade

with

Repros Therapeutics Inc
(NASDAQ: RPRX)
AdChoices
6.02
-0.21
-3.37%
After Hours :
6.68
+0.66
+10.96%

Open

6.38

Previous Close

6.23

Volume (Avg)

1.39M (1.11M)

Day's Range

5.92-6.38

52Wk Range

5.92-24.33

Market Cap.

139.12M

Dividend Rate ( Yield )

-

Beta

0.91

Shares Outstanding

23.11M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 9.00k

    • Net Income

    • -27.72M

    • Market Cap.

    • 139.12M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -253,266.67

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.91

    • Forward P/E

    • -3.52

    • Price/Sales

    • 10,000.00

    • Price/Book Value

    • 2.31

    • Price/Cash flow

    • -5.45

      • EBITDA

      • -27.46M

      • Return on Capital %

      • -39.24

      • Return on Equity %

      • -41.38

      • Return on Assets %

      • -39.24

      • Book Value/Share

      • 2.60

      • Shares Outstanding

      • 23.11M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 41.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.63

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 100.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -53.92

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -253,266.67

            • 39.38

            • Net Profit Margin

            • -253,266.67

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -308,840.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 14.94

              • 2.92

              • Quick Ratio

              • 14.85

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.07

              • 2.21

              • Book Value/Share

              • 2.60

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.73

                • 196.08

                • P/E Ratio 5-Year High

                • -22.60

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.84

                • 124.82

                • Price/Sales Ratio

                • 10,000.00

                • 9.12

                • Price/Book Value

                • 2.39

                • 8.26

                • Price/Cash Flow Ratio

                • -5.45

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -41.38

                    (-219.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -39.24

                    (-148.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -41.38

                    (-219.80)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.00

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -27.72M
                  Operating Margin
                  -308,011.11
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -5.45
                  Ownership

                  Institutional Ownership

                  96.06%

                  Top 10 Institutions

                  63.38%

                  Mutual Fund Ownership

                  26.65%

                  Float

                  87.56%

                  5% / Insider Ownership

                  0.75%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Biotechnology Discovery

                  •  

                    1,668,600

                  • 72.80

                  • 7.22

                  • SPDR® S&P Pharmaceuticals ETF

                  •  

                    746,225

                  • 0.00

                  • 2.03

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    717,300

                  • 0.00

                  • 3.10

                  • Janus Global Life Sciences Fund

                  •  

                    653,542

                  • 3.19

                  • 2.83

                  • iShares Russell 2000 (AU)

                  •  

                    357,582

                  • -1.01

                  • 0.97

                  • Vanguard Total Stock Mkt Idx

                  •  

                    350,577

                  • 0.00

                  • 1.52

                  • Invesco Global Health Care Fd

                  •  

                    266,788

                  • 0.00

                  • 1.14

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    211,800

                  • 0.00

                  • 0.92

                  • Vanguard Extended Market Index Fund

                  •  

                    203,186

                  • 0.00

                  • 0.88

                  • iShares Russell 2000 Growth

                  •  

                    164,413

                  • -2.72

                  • 0.45

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Baker Bros Advisors LLC

                  •  

                    2,778,654

                  • 0.00%

                  • 12.02

                  • Visium Asset Management LLC

                  •  

                    1,840,799

                  • 0.00%

                  • 7.97

                  • Oracle Investment Management Inc

                  •  

                    1,267,126

                  • +2.00%

                  • 5.48

                  • RA Capital Management, LLC

                  •  

                    1,219,381

                  • -15.26%

                  • 5.28

                  • Sarissa Capital Management LP

                  •  

                    1,003,367

                  • +78.98%

                  • 4.34

                  • State Street Corp

                  •  

                    921,128

                  • -15.23%

                  • 3.99

                  • Partner Fund Management LP

                  •  

                    850,942

                  • -23.65%

                  • 3.68

                  • BlackRock Fund Advisors

                  •  

                    801,995

                  • +0.48%

                  • 3.47

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Repros Therapeutics Inc was organized on August 20, 1987. The Company is a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's main pr...moreoduct candidate, Androxal, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. It is developing Androxal for men of reproductive age with low testosterone levels. Androxal treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. The Company’s second product candidate, Proellex for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fi...morebroids and endometriosis. The Company recently completed a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex. The Company's research and development activities, preclinical studies and clinical trials, and the manufacturing, marketing and labeling of any products it may develop, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries.lessless

                  Key People

                  Joseph S. Podolski

                  CEO/Director/President

                  Nola E. Masterson,PhD

                  Chairman of the Board/Director

                  Ms. Katherine A. Anderson

                  CFO/Chief Accounting Officer/Secretary

                  Dr. Ronald Wiehle,PhD

                  Vice President, Divisional

                  Daniel F. Cain

                  Director

                  • Repros Therapeutics Inc

                  • 2408 Timberloch Place

                  • The Woodlands, TX 77380

                  • USA.Map

                  • Phone: +1 281 719-3400

                  • Fax: +1 281 719-3446

                  • reprosrx.com

                  Incorporated

                  1987

                  Employees

                  28

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: